AMED News and Press, Amedisys Inc From 11/17/22

Amedisys Confirms Full Year Guidance PR Newswire BATON ROUGE, La. , Nov. 17, 2022 /PRNewswire/ -- Today, the Board of Directors of Amedisys, Inc. (NASDAQ: AMED) announced a leadership change that President and Chief Executive Officer, Chris Gerard , will ...

Amedisys Announces CEO Departure PR Newswire Paul Kusserow returns as Chairman and CEO BATON ROUGE, La. , Nov. 17, 2022 /PRNewswire/ -- Today, the Board of Directors of Amedisys, Inc. (NASDAQ: AMED) announced that President and Chief Executive...

BATON ROUGE, La., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, issued the following statement following the CY 2023 Home Health Final Rule by the Centers for Medicare and Medicaid Ser...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Amedisys, Inc. (AMED) Q3 2022 Earnings Conference Call October 27, 2022 11:00 AM ET Company Participants Nick Muscato – Chief Strategy Officer Chris Gerard – President and Chief Executive Officer Scott Ginn – Executive Vice President and Chie...

The following slide deck was published by Amedisys, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Amedisys, Inc. 2022 Q3 - Results - Earnings Call Presentation

Amedisys, Inc. ( NASDAQ: AMED ) crashed 12% after reporting lower-than-expected financials for 2022 Q3, and Ramond James downgraded it to Market Perform from Outperform, arguing that the healthcare services company lowered its EBITDA outlook for the second time this year. ...

Amedisys ( NASDAQ: AMED ) stock fell ~15% premarket on Thursday after Q3 results missed estimates and the company lowered its FY22 adjusted EPS outlook. Q3 adjusted EPS declined -24.8% Y/Y to $1.15, while net service revenue was largely flat (+0.8%) Y/Y to $558M....

Amedisys press release ( NASDAQ: AMED ): Q3 Non-GAAP EPS of $1.15 misses by $0.07 . Revenue of $558.92M (+1.0% Y/Y) misses by $20.38M . Shares +3.37% . For further details see: Amedisys  Non-GAAP EPS of $1.15 misses by $0.07, revenue of $...

BATON ROUGE, La., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2022. Three-Month Periods Ended September 30, 2022 and 2021 Net service revenue increased...